LeadArtis is currently funded by Growth Factor Biocapital, Bionexum Ventures and other angel investors as well as with non-dilutive grants.
R&D activities, facilities and equipment have been co-financed by the Spanish Ministry of Economy and Competitiveness (Torres Quevedo Program calls 2009, 2011, 2013 and 2017) and the RETOS Collaboration program 2014 and 2016 calls; by the RIS3 innovation program from the Comunidad de Madrid regional initiative; and by the 7th European Framework Program (FP7) in addition to private funds. Additionally, we have received support by the Genoma España Foundation and by the Carlos III Health Institute.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...